CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SynBiotic SE is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SynBiotic SE
Muensterstrasse 336
MUENCHEN, 40470  Germany Ticker: SBXSBX

Business Summary
SynBiotic SE is a Germany-based investment company. Mainly the Company invests in cannabinoid focused ventures and teams.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Supervisory Board SebastianStietzel
Chief Executive Officer DanielKruse 8/21/2023 8/21/2023
Chief Executive Officer of Greenlight Pharmaceutical Ltd Le RoyDowey
4 additional Officers and Directors records available in full report.

Business Names
Business Name
L3D
L3DA
SBX

General Information
Number of Employees: 55 (As of 12/31/2023)
Outstanding Shares: 5,145,116 (As of 12/31/2023)
Stock Exchange: ETR


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024